Skip to Main Content

Paper Details

Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Clin Cancer Res
0
2023
Advanced Leiomyosarcoma, B-cell, CD8, CD8 T cells, Cediranib, Durvalumab, M1, M1-macrophage, Olaparib, PARP, Patients, cediranib, immune cell, leiomyosarcoma, macrophages, olaparib, patient, patients, tumor, tumors
Author NameAffiliation
Hal K BermanPrincess Margaret Cancer Centre, University Health Network, University of Toronto
Philippe L BedardPrincess Margaret Cancer Centre, University Health Network, University of Toronto
Benjamin Haibe-KainsUniversity of Toronto
Benjamin Haibe-KainsUniversity of Toronto
Lillian L SiuPrincess Margaret Cancer Centre, University Health Network, University of Toronto
  • 1 - 5

Datasets

Release 1.2